drugset / Trial / NCT06024642
Study of V117957 in Overactive Bladder Syndrome
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2024-05-21
- Completion
- 2024-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunobinop | Small molecule | 1 mg | Oral |